Expression of SIRT1 in ocular surface squamous neoplasia

Cornea

Volumn 31, Issue 7, 2012, Pages 817-819

  Alves, Luiz Filipe De A ^a,b,c   Fernandes, Bruno F ^b   Burnier, Julia V ^b   Mansure, José J ^b   Maloney, Shawn ^b   Odashiro, Alexandre N ^b   Antecka, Emilia ^b   De Souza, Dominique F ^b   Burnier Jr , Miguel N ^b  

^a Brazilian Air Force Central Hospital Rio de Janeiro   (Brazil)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

conjunctiva; immunohistochemistry; neoplasia; pathology

Indexed keywords

SIRTUIN 1;

ARTICLE; BASEMENT MEMBRANE; CELL NUCLEUS; CLINICAL ARTICLE; CONJUNCTIVA TUMOR; CORRELATION ANALYSIS; CYTOPLASM; DISEASE COURSE; ELASTOSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; OCULAR SURFACE DISEASE; OCULAR SURFACE SQUAMOUS NEOPLASIA; PAPILLOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE;

CARCINOMA IN SITU; CARCINOMA, SQUAMOUS CELL; CONJUNCTIVAL NEOPLASMS; EPITHELIAL CELLS; HUMANS; IMMUNOENZYME TECHNIQUES; NEOPLASM PROTEINS; PAPILLOMA; SIRTUIN 1; TUMOR MARKERS, BIOLOGICAL;

EID: 84862862000     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0b013e31823f7857     Document Type: Article

References (16)

1. Stunkel W, Peh BK, Tan YC, et al. Function of the SIRT1 protein deacetylase in cancer. Biotechnol J. 2007;2:1360-1368. (Pubitemid 350176266)
2. Kim EJ, Um SJ. SIRT1: roles in aging and cancer. BMB Rep. 2008;41: 751-756.
3. Huffman DM, Grizzle WE, Bamman MM, et al. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res. 2007;67: 6612-6618. (Pubitemid 47105506)
4. Bradbury CA, Khanim FL, Hayden R, et al. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia. 2005;19: 1751-1759. (Pubitemid 41486152)
5. Lim CS. SIRT1: tumor promoter or tumor suppressor? Med Hypotheses. 2006;67:341-344.
6. Ogun GO, Ogun OA, Bekibele CO, et al. Intraepithelial and invasive squamous neoplasms of the conjunctiva in Ibadan, Nigeria: a clinicopath-ological study of 46 cases. Int Ophthalmol. 2009;29:401-409.
7. Lee GA, Hirst LW. Ocular surface squamous neoplasia. Surv Ophthal-mol. 1995;39:429-450.
8. Pe'er J. Ocular surface squamous neoplasia. Ophthalmol Clin North Am. 2005;18:1-13.
9. Remmele W, Stegner HE. [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe. 1987;8:138-140.
10. Imai S, Armstrong CM, Kaeberlein M, et al. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature. 2000;403:795-800. (Pubitemid 30111843)
11. Motta MC, Divecha N, Lemieux M, et al. Mammalian SIRT1 represses forkhead transcription factors. Cell. 2004;116:551-563. (Pubitemid 38264432)
12. Hida Y, Kubo Y, Murao K, et al. Strong expression of a longevity-related protein, SIRT1, in Bowen's disease. Arch Dermatol Res. 2007;299:103-106. (Pubitemid 46669407)
13. Mahomed A, Chetty R. Human immunodeficiency virus infection, Bcl-2, p53 protein, and Ki-67 analysis in ocular surface squamous neoplasia. Arch Ophthalmol. 2002;120:554-558. (Pubitemid 34496605)
14. El-Khoury V, Moussay E, Janji B, et al. The histone deacetylase inhibitor MGCD0103 induces apoptosis in B-cell chronic lymphocytic leukemia cells through a mitochondria-mediated caspase activation cascade. Mol Cancer Ther. 2010;9:1349-1360.
15. Fournel M, Bonfils C, Hou Y, et al. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther. 2008;7:759-768. (Pubitemid 351551029)
16. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol. 2009;27:5459-5468.